GlassScriptPhysician profile
Brian L Mcgee
NPI 1497979652
$4,801.67
in general payments reported to CMS, 2019-2025
29 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $543 · 2021: $1,262 · 2022: $995 · 2023: $299 · 2024: $346 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,596.13 | 2019-2024 | |
| Gilead Sciences, INC. | $482.53 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.55 | 2019-2023 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $329.94 | 2022-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $310.94 | 2024-2025 | Voquezna |
| Pfizer INC. | $264.45 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $219.34 | 2019-2023 | Ocaliva |
| Redhill Biopharma INC. | $178.85 | 2021-2023 | Talicia |
| Allergan, INC. | $129.63 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $119.92 | 2020-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $108.11 | 2019-2020 | |
| Evoke Pharma, INC. | $67.42 | 2021-2022 | |
| Medtronic, INC. | $64.63 | 2023-2025 | Interstim |
| Madrigal Pharmaceuticals | $44.27 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41.52 | 2024-2025 | Omvoh |
| Bayer Healthcare Pharmaceuticals INC. | $39.90 | 2019-2020 | |
| Celgene Corporation | $26.60 | 2022-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $23.79 | 2025 | Zenpep |
| Micro-Tech Endoscopy USA, INC. | $23.78 | 2024 | Blueboost |
| Otsuka America Pharmaceutical, INC. | $22.00 | 2025 | Abilify Asimtufii |
| Alnylam Pharmaceuticals INC. | $18.30 | 2022 | |
| Celltrion USA INC. | $17.47 | 2025 | Vegzelma |
| Novo Nordisk INC | $15.00 | 2025 | Wegovy |
| Olympus America INC. | $14.38 | 2021 | |
| Dova Pharmaceuticals | $14.25 | 2020 | |
| Ardelyx, INC. | $13.55 | 2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $12.72 | 2019 | |
| Enterra Medical, INC. | $12.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.